Cargando…

GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly reduce postprandial blood glucose, inhibit appetite, and delay gastrointestinal emptying. However, it is controversial that some patients are intolerant to GLP-1RAs. METHODS: PubMed, Embase, Web of Science, and Cochrane L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ziqi, Zhang, Qiling, Tan, Ying, Chen, Yu, Zhou, Xiqiao, Liu, Su, Yu, Jiangyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359616/ https://www.ncbi.nlm.nih.gov/pubmed/37484944 http://dx.doi.org/10.3389/fendo.2023.1149328

Ejemplares similares

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Corrigendum: The value of functional magnetic resonance imaging in the evaluation of diabetic kidney disease: a systematic review and meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

The value of functional magnetic resonance imaging in the evaluation of diabetic kidney disease: a systematic review and meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
por: Zhou, Peipei, et al.
Publicado: (2023)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study
por: Tan, Ying, et al.
Publicado: (2023)

The central GLP-1: implications for food and drug reward
por: Skibicka, Karolina P.
Publicado: (2013)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
por: Pan, Xiaohui, et al.
Publicado: (2020)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Circadian secretion rhythm of GLP-1 and its influencing factors
por: Liu, Chuanfeng, et al.
Publicado: (2022)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

Gastrointestinal Distension by Pectin-Containing Carbonated Solution Suppresses Food Intake and Enhances Glucose Tolerance via GLP-1 Secretion and Vagal Afferent Activation
por: Ohbayashi, Kento, et al.
Publicado: (2021)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
por: Meng, Zhuqing, et al.
Publicado: (2023)

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease
por: Liu, Jia, et al.
Publicado: (2017)

The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism
por: Danowitz, Melinda, et al.
Publicado: (2022)

Emerging Role of Caveolin-1 in GLP-1 Action
por: Puddu, Alessandra, et al.
Publicado: (2021)

GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics
por: Wright, Shane C., et al.
Publicado: (2023)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Psychiatric Comorbidities and Liver Injury Are Associated With Unbalanced Plasma Bile Acid Profile During Methamphetamine Withdrawal
por: Ma, Yuru, et al.
Publicado: (2022)

Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes
por: Huang, Yuxin, et al.
Publicado: (2022)

GLP-1 based therapeutics: simultaneously combating T2DM and obesity
por: Heppner, Kristy M., et al.
Publicado: (2015)

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
por: Rowlands, Jordan, et al.
Publicado: (2018)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
por: Li, Qiu-Xuan, et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study
por: Tsai, Chih-Yiu, et al.
Publicado: (2022)

The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis
por: Chen, Juan, et al.
Publicado: (2020)

c-Myc Upregulated by High Glucose Inhibits HaCaT Differentiation by S100A6 Transcriptional Activation
por: Zhang, Jie, et al.
Publicado: (2021)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
por: Hu, Weiting, et al.
Publicado: (2022)

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
por: Foley, James E.
Publicado: (2019)

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
por: Tanday, Neil, et al.
Publicado: (2021)

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake
por: Ouberai, Myriam M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h97h9a7kfftt2b9dbd10jrvlbq